Cover Image

Comparative Pharmacokinetics and Safety of Imrecoxib, a Novel Selective Cyclooxygenase-2 Inhibitor, in Elderly Healthy Subjects

Ling Yang &ast;, Qi Shen &ast;, Chao Hu, Ying Wang, Xiaohong Zhu, Shiqing Shu, Zhu Luo Clinical Trial Center, National Medical Products Administration Key Laboratory for Clinical Research and Evaluation of Innovative Drugs, West China Hospital Sichuan University, Chengdu, People's Repub...

Full description

Saved in:

Bibliographic Details
Main Authors:	Yang L (Author), Shen Q (Author), Hu C (Author), Wang Y (Author), Zhu X (Author), Shu S (Author), Luo Z (Author)
Format:	Book
Published:	Dove Medical Press, 2022-11-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Imrecoxib: Advances in Pharmacology and Therapeutics
by: Wang YH, et al.
Published: (2024)

Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy adult male subjects
by: Shen Z, et al.
Published: (2017)

A Real-World Study on the Effect of Imrecoxib for Patients with Axial Spondyloarthritis
by: Zong HX, et al.
Published: (2022)

Pharmacokinetics, pharmacodynamics, and safety of lesinurad, a selective uric acid reabsorption inhibitor, in healthy adult males
by: Shen Z, et al.
Published: (2015)

Pharmacokinetics and Safety of the Tyrosine Kinase 2 Inhibitor Deucravacitinib in Healthy Chinese Subjects
by: Shan Jing, et al.
Published: (2023)

Pharmacokinetics, pharmacodynamics and safety of CKD-519, a CETP inhibitor, in healthy subjects
by: Kim CO, et al.
Published: (2016)

Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy Japanese and non-Asian male subjects
by: Hall J, et al.
Published: (2018)

Pharmacokinetic, Pharmacokinetic/Pharmacodynamic, and Safety Investigations of Lefamulin in Healthy Chinese Subjects
by: Yingying Hu, et al.
Published: (2023)

Evaluation of Olaparib Tablet Safety and Pharmacokinetics in Healthy Chinese Male Subjects
by: Dong R, et al.
Published: (2024)

Pharmacokinetic and Safety Study of Bismuth Potassium Citrate Formulations in Healthy Subjects
by: Hong-Yu Luo, et al.
Published: (2024)

Pharmacokinetics, Safety and Pharmacokinetics/Pharmacodynamics Analysis of Omadacycline in Chinese Healthy Subjects
by: Haijing Yang, et al.
Published: (2022)

Safety, Pharmacokinetics, and Pharmacodynamics of ASP3662, a Novel 11β‐Hydroxysteroid Dehydrogenase Type 1 Inhibitor, in Healthy Young and Elderly Subjects
by: Susan Bellaire, et al.
Published: (2019)

Pharmacokinetics and safety of repirinast tablets in healthy Chinese subjects
by: Cheng-zhe Lv, et al.
Published: (2018)

Effect of High-Fat Meal on the Pharmacokinetics and Safety of Valsartan/Amlodipine Fixed Dose Combination Tablets in Healthy Subjects
by: Song H, et al.
Published: (2024)

A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TPN171H, a Novel Phosphodiesterase Type 5 Inhibitor, in Healthy Subjects
by: Qian H, et al.
Published: (2021)

Pharmacokinetics, safety, and tolerability of gepotidacin administered as single or repeat ascending doses, in healthy adults and elderly subjects
by: Courtney Tiffany, et al.
Published: (2022)

The effect of food on the pharmacokinetics of WXFL10203614, a potential selective JAK1 inhibitor, in healthy Chinese subjects
by: Kai Huang, et al.
Published: (2022)

Safety, tolerability, and pharmacokinetics of fluoropezil (DC20), a novel acetylcholinesterase inhibitor: A phase I study in healthy young and elderly Chinese subjects
by: Hongjie Qian, et al.
Published: (2023)

Comparison of the Pharmacokinetics, Safety, and Tolerability of Two Empagliflozin Formulations in Healthy Korean Subjects
by: Jiang X, et al.
Published: (2023)

Safety, Tolerability, and Pharmacokinetics of Remdesivir, An Antiviral for Treatment of COVID‐19, in Healthy Subjects
by: Rita Humeniuk, et al.
Published: (2020)

Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects
by: Cui Y, et al.
Published: (2013)

Reduction in cancer risk by selective and nonselective cyclooxygenase-2 (COX-2) inhibitors
by: Harris RE, et al.
Published: (2012)

Discovery of Bis-sydnone styryl ketone as a selective cyclooxygenase-2 inhibitor
by: Abdualrahman Mohammed Abdualkader, et al.
Published: (2021)

Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Benfotiamine in Healthy Subjects
by: Sheng L, et al.
Published: (2021)

Safety, Tolerability, and Pharmacokinetics of the β‐Site Amyloid Precursor Protein‐Cleaving Enzyme 1 Inhibitor Verubecestat (MK‐8931) in Healthy Elderly Male and Female Subjects
by: Mark Forman, et al.
Published: (2019)

Pharmacokinetics and tolerability of DA-8031, a novel selective serotonin reuptake inhibitor for premature ejaculation in healthy male subjects
by: Shin D, et al.
Published: (2017)

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Sotagliflozin After Multiple Ascending Doses in Chinese Healthy Subjects
by: He X, et al.
Published: (2022)

First-In-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of SHR2285, a Small-Molecule Factor XIa Inhibitor in Healthy Subjects
by: Rui Chen, et al.
Published: (2022)

Pharmacokinetics and Safety of Doripenem in Healthy Chinese Subjects and Monte Carlo Dosing Simulations
by: Yu Wang, et al.
Published: (2022)

A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Novel Intravenous Formulation of Meloxicam (QP001) in Healthy Chinese Subjects
by: Ma J, et al.
Published: (2023)

Safety, tolerability, pharmacokinetic/pharmacodynamic characteristics of bersiporocin, a novel prolyl‐tRNA synthetase inhibitor, in healthy subjects
by: Min Young Park, et al.
Published: (2023)

Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects [Corrigendum]
by: Cui Y, et al.
Published: (2014)

Pharmacokinetics and Safety of Single and Multiple Doses of Peficitinib (ASP015K) in Healthy Chinese Subjects
by: Gao X, et al.
Published: (2022)

Effect of Food on the Pharmacokinetics and Safety of a Novel c-Met Inhibitor SCC244: A Randomized Phase I Study in Healthy Subjects
by: Wu J, et al.
Published: (2023)

Cyclooxygenase (COX) Inhibitors and the Newborn Kidney
by: Wei Qi, et al.
Published: (2012)

Cyclooxygenase-2 inhibitors: promise or peril?
by: Laurel J. Mengle-Gaw, et al.
Published: (2002)

Pharmacokinetics and Bioequivalence of Apremilast Tablets in Chinese Healthy Subjects Under Fasting and Postprandial States
by: Bai W, et al.
Published: (2024)

A phase I randomized, double‐blinded, placebo‐controlled study assessing the safety and pharmacokinetics of RIPK1 inhibitor GFH312 in healthy subjects
by: Jason Lickliter, et al.
Published: (2023)

Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of Pelmeg®, a pegfilgrastim biosimilar in healthy subjects
by: Karsten Roth, et al.
Published: (2019)

Single- and multiple-dose tolerability, safety, pharmacokinetics, and pharmacodynamics of the dual endothelin receptor antagonist aprocitentan in healthy adult and elderly subjects
by: Sidharta PN, et al.
Published: (2019)